Cargando…

Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease

Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other t...

Descripción completa

Detalles Bibliográficos
Autores principales: Stec, Rafał, Grala, Bartłomiej, Mączewski, Michał, Bodnar, Lubomir, Szczylik, Cezary
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764641/
https://www.ncbi.nlm.nih.gov/pubmed/19811659
http://dx.doi.org/10.1186/1756-9966-28-134
_version_ 1782173106820874240
author Stec, Rafał
Grala, Bartłomiej
Mączewski, Michał
Bodnar, Lubomir
Szczylik, Cezary
author_facet Stec, Rafał
Grala, Bartłomiej
Mączewski, Michał
Bodnar, Lubomir
Szczylik, Cezary
author_sort Stec, Rafał
collection PubMed
description Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC. Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.
format Text
id pubmed-2764641
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27646412009-10-21 Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease Stec, Rafał Grala, Bartłomiej Mączewski, Michał Bodnar, Lubomir Szczylik, Cezary J Exp Clin Cancer Res Review Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC. Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies. BioMed Central 2009-10-07 /pmc/articles/PMC2764641/ /pubmed/19811659 http://dx.doi.org/10.1186/1756-9966-28-134 Text en Copyright © 2009 Stec et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Stec, Rafał
Grala, Bartłomiej
Mączewski, Michał
Bodnar, Lubomir
Szczylik, Cezary
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title_full Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title_fullStr Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title_full_unstemmed Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title_short Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
title_sort chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764641/
https://www.ncbi.nlm.nih.gov/pubmed/19811659
http://dx.doi.org/10.1186/1756-9966-28-134
work_keys_str_mv AT stecrafał chromophoberenalcellcancerreviewoftheliteratureandpotentialmethodsoftreatingmetastaticdisease
AT gralabartłomiej chromophoberenalcellcancerreviewoftheliteratureandpotentialmethodsoftreatingmetastaticdisease
AT maczewskimichał chromophoberenalcellcancerreviewoftheliteratureandpotentialmethodsoftreatingmetastaticdisease
AT bodnarlubomir chromophoberenalcellcancerreviewoftheliteratureandpotentialmethodsoftreatingmetastaticdisease
AT szczylikcezary chromophoberenalcellcancerreviewoftheliteratureandpotentialmethodsoftreatingmetastaticdisease